Actelion reviews satisfactory 2000
Actelion of Switzerland, which recently reported an 11-fold rise inoperating income for 2000 of 31.6 million Swiss francs ($19.1 million; Marketletter February 19), has been reflecting on its successes last year and has given an update on its two lead compounds, for which "decisive clinical trial results" are expected during 2001.
The firm's endothelin receptor antagonist Tracleer (bosentan) should be its first to reach the market, for chronic heart failure, swiftly followed by Veletri (tezosentan) for acute heart failure. Actelion also noted that Tracleer is currently under regulatory review in both the USA and Europe for the treatment of pulmonary arterial hypertension.
Actelion's chief executive, Jean-Paul Clozel, said he is pleased with the company's achievements "in what is only our third year of operations." He added that both Veletri and Tracleer have shown great promise in previous clinical studies and, if these are confirmed by the ongoing trials, "we are prepared to file for regulatory review as soon as the results are in."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze